An interventional study of LUCIOLE CAP and LUCIOLE CAP (sham version) in Photobiomodulation and Dementia With Lewy Bodies, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Lewy Body Disease with a site in France — 9 open to participants now, 9 under way, 1 of them phase 3. Lewy Body Disease · France.
Among the 30 studies in Lewy Body Disease with a site in France, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 30th registered.
240 studies on the registry are indexed under Lewy Body Disease; 89 are open to participants now.
Browse Lewy Body Disease studies →9 of the 30 studies in Lewy Body Disease with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90 · Healthy volunteers
ACADIA Pharmaceuticals Inc. · Sites in France, United States, Bulgaria and 3 more countries
Ages 55–84
ACADIA Pharmaceuticals Inc. · Sites in France, United States, Bulgaria and 3 more countries
Ages 55–84
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 64 Lewy Body Disease studies recruiting now, 42 (66%) set no upper age limit and none (0%) stop at 75 or younger; 10 take children under 18; 31 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 4
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 86 across 152 interventional studies indexed under Lewy Body Disease.
Median enrollment 130 across the 22 interventional studies, 228 across the 8 observational. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 30 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 7 studies filed under Lewy Body Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Lewy Body Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05977712Assistance Publique - Hôpitaux de ParisCircadian Rhythm and Other Factors in Memory Clinic Patients | 2027-03 |
| NCT06439355Centre Hospitalier Universitaire DijonSingle-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis | 2027-05 |
| NCT04389437Fondation Ophtalmologique Adolphe de RothschildOCT-Angiography and Adaptive Optics in Patients With Memory Impairment | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Lewy Body Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dementia with Lewy bodies (DLB) is a neurodegenerative disease diagnosed primarily based on the presence of cognitive decline, which may include difficulties with memory, attention, and more. Additionally, at least two of the following symptoms are needed for a probable diagnosis of DLB, and at least one for a possible DLB diagnosis (McKeith et al. 2017 and 2020):
Patients with DLB can experience cognitive deficits that can fluctuate and can vary for each patient. These may include deficits in memory, executive functions (planning and organizing), attention, visual processing, and language.
This study aims to evaluate the effect of red-light therapy, delivered using a helmet that contains small LED lights, in patients with DLB.
Participants' cognitive functions, clinical symptoms, quality of life and functional cerebral connectivity will be evaluated before starting therapy and again after three and six months of twice daily therapy use. As DLB also indirectly affects caregivers, the caregiver's quality of life and burden will also be evaluated before and at three and six months of therapy use by the participant.
The study's inclusion period is 24 months and the duration of participation for each patient is 8 months (+/-10 days) maximum.
Dementia with Lewy bodies (DLB) is the second most frequent neurodegenerative disease after Alzheimer's disease and represents 15 to 20% of dementia cases (Ballard et al. 2001; Zaccai et al. 2005; Aarsland et al. 2008). DLB is diagnosed primarily based on the presence of cognitive decline, which is most often perceived as difficulties relating to attention, visuospatial capacities and executive functions like planning, decision making and more.
Additionally, at least two of the following core clinical symptoms are needed for a probable diagnosis of DLB, and at least one for a possible DLB diagnosis (McKeith et al. 2017 and 2020):
Suggestive symptoms may support the diagnosis of probable DLB when at least one core clinical symptom is present together with one of the following features, or possible DLB when one or more of the following features are present in the absence of any core clinical feature (McKeith et al. 2017 and 2020):
There is currently no treatment for DLB (Mueller et al. 2017). The effectiveness of available symptomatic treatments is also limited and sometimes accompanied by severe side effects (Boot et al. 2013; Boot, 2015). There is therefore an urgent need to develop therapeutic solutions adapted to DLB, aiming at neuroprotection and/or improvement of the quality of life of patients through better management of clinical symptoms. We are particularly interested in non-invasive and non-pharmacological approaches, with the aim of identifying methods without side effects and can easily be used by patients daily.
In this context, a new approach is the subject of growing interest within the medical and scientific communities, as well as the general public. Known as photobiomodulation (PBM), this technique involves applying red to infrared light (λ=600-1000nm) on biological tissues.
This study aims to evaluate the effect of transcranial PBM in patients with DLB.
Participants' cognitive functions, clinical symptoms, quality of life and cerebral connectivity will be evaluated before starting therapy and again after three and six months of twice daily therapy use. As DLB also indirectly affects caregivers, the caregiver's quality of life and burden will also be evaluated before and at three and six months of therapy use by the participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants assigned to the active group will each receive an active LUCIOLE cap to be used at home twice daily for six months with the assistance of their caregiver. A minimum interval of four hours is required between the two daily sessions. Each session lasts for 32 minutes (including 24 minutes of active near-infrared red light and 8 minutes of cooling periods spaced throughout the session). The cap automatically turns off at the end of each session. The caregiver assists the participant in placing the cap on correctly, verifies that the cap works properly, and starts the session. All participants in the active group will undergo neuropsychological evaluations, clinical and neurological examinations, MRIs, and blood tests and at months 0, 3 and 6 of the study. Participants will also be evaluated at month 7, one month after the end of the photobiomodulation sessions, during which the same clinical, neurological and neuropsychological evaluations will be administered.
Device: LUCIOLE CAP
Participants in the sham group will follow the same PBM schedule as the participants in the active group: twice daily sessions of 32 minutes for six months (see active group description for more information) except they will use the sham LUCIOLE cap. The sham cap mimics the appearance, heating and operation of the active cap but does not deliver PBM. The only difference between the two versions is in the internal electronics and firmware modifications. The two versions can only be differentiated by their serial numbers. All participants in the study, as well as the research team, do not know which caps are active and which are sham. As in the active group, participants in the sham group will undergo neuropsychological evaluations, clinical and neurological examinations, MRIs, and blood tests and at months 0, 3 and 6 of the study. Participants will also be seen at month 7, one month after the end of the PBM sessions, for clinical, neurological and neuropsychological evaluations.
Device: LUCIOLE CAP (sham version)
The LUCIOLE Cap is a medical device (without CE mark) designed for transcranial photobiomodulation (PBM). The cap was developed specifically for this purpose by the CLINATEC Endowment Fund (FDC), and it has not been used in any clinical investigation before. The LUCIOLE Cap will be used for the first time in this study with patients diagnosed with Dementia with Lewy bodies. The LUCIOLE cap is a non-invasive device that delivers PBM to the brain by shining light through the skin and bone. The LEDs emit near-infrared-light at a wavelength of 810 nm, with an illumination power of up to 8W (\~40mW/cm²). For safety, the cap must only be used in the room chosen by the study investigator during the first home visit. It must be used in a dry environment, away from sources of water or moisture, avoiding direct sunlight, and at a room temperature between 5°C and 27.5°C.
The CLINATEC Endowment Fund (FDC) designed this sham cap exclusively for scientific studies. It is built specifically to provide an accurate comparison against the active cap. This precise control allows investigators to clearly evaluate whether the active LUCIOLE cap delivers true, measurable benefits. The sham cap mimics the active LUCIOLE cap's operational characteristics and heat output without delivering actual PBM. The devices look identical and are distinguishable only by their serial numbers. This internal difference in electronics and firmware guarantees that both clinical investigators and participants remain blinded to the treatment allocation. For safety, the cap must only be used in the room chosen by the study investigator during the first home visit. It must be used in a dry environment, away from sources of water or moisture, avoiding direct sunlight, and at a room temperature between 5°C and 27.5°C.
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
(Randolph et al., 1998)
Time frame: Measurements done right before start of PBM (at month 0 (M0)), after 3 months of PBM (M3), after six months of PBM (M6), and one month after end of PBM (M7)
Started Sep 2026 (actual). Primary completion is estimated for May 2029, 32 months after the start.
Of 59 non-industry interventional studies with no phase under Lewy Body Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 53. This study's planned 32 months is close to that.
Counting every sponsor, half of 63 studies reached it within 35 months; a quarter within 26 and three quarters within 56.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jun 2026 → Sep 2026, primary completion Dec 2028 → May 2029 and completion Mar 2029 → May 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →